AstraZeneca (NASDAQ:AZN) plans to invest $50 billion to strengthen its U.S. manufacturing and research capabilities by 2030, the company announced Monday.
The Anglo-Swedish biotech company said the centerpiece of this commitment will be a new multi-billion dollar manufacturing facility in Virginia focused on producing its weight management and metabolic portfolio, including its oral GLP-1 obesity pill.
This Virginia facility is set to become AstraZeneca’s largest single manufacturing investment globally.
The company stated the new plant will incorporate AI, automation and data analytics to optimize production processes.
The investment plan also includes expanding research and development and cell therapy manufacturing operations across multiple states including Maryland, Massachusetts, California, Indiana and Texas.
AstraZeneca said the initiative will create tens of thousands of jobs across these locations.
The company joins other pharmaceutical firms that have recently increased their U.S. investments following the implementation of U.S. trade tariffs.
